Clinical trials: Recurrent or Metastatic Nasopharyngeal Carcinoma
- Condition Recurrent or Metastatic Nasopharyngeal Carcinoma
- Funder type Industry (pharma, biotech, devices)
Recurrent or Metastatic Nasopharyngeal Carcinoma
A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
This is a randomized, open-label, multi-center, phase III study to evaluate the efficacy and safety, and immunogenicity of MRG003 in combination with pucotenlimab in patients with recurrent or metastatic nasopharyngeal carcinoma.
- Trial name
- Magic-C002 (NCT06976190)
- Testing
- MRG003 + Pucotenlimab, Gemcitabine, Docetaxel, or Capecitabine
- Where
- China
- Volunteers
- 446 people
- Sponsor
- Lepu Biopharma Co., Ltd.
Recurrent or Metastatic Nasopharyngeal Carcinoma
A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma
The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG003 in patients with recurrent metastatic nasopharyngeal carcinoma.
- Trial name
- NCT05126719
- Testing
- MRG003, Capecitabine tablets, Docetaxel injection
- Where
- 23 sites in China
- Volunteers
- 238 people
- Sponsor
- Lepu Biopharma Co., Ltd.
Nasopharyngeal Carcinoma
A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma (TAISHAN-301)
This study was designed to compare the efficacy and safety of YL201 with Investigator's choice of chemotherapy in subjects with recurrent or metastatic nasopharyngeal carcinoma who have failed prior PD-(L)1 inhibitor and at least…
- Trial name
- NCT06629597
- Testing
- YL201, Docetaxel, Capecitabine
- Where
- China
- Volunteers
- 400 people
- Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
Nasopharyngeal Carcinoma (NPC)
A Study of Anti-PD-1 Antibody With or Without BL-B01D1 as Maintenance Therapy Following Anti-PD-1 Antibody Plus Chemotherapy for the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma (PANKU-NPC02)
This trial is a registrational Phase III, randomized, open-label, multicenter study designed to evaluate the efficacy and safety of PD-1 monoclonal antibody combined with chemotherapy, followed by maintenance therapy with PD-1…
- Trial name
- NCT07783321
- Testing
- BL-B01D1, PD-1 monoclonal antibody, cisplatin
- Where
- China
- Volunteers
- 404 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
NPC, HNSCC
A Clinical Trial to Evaluate Effect of IAE0972 Combined with Chemotherapy for R/M HNSCC or NPC(Note: It is Currently Phase II.).
Phase II: To evaluate the safety and tolerability of IAE0972 combined with chemotherapy selected by doctors for R/M HNSCC/NPC after failure or progress of ≤2-line system therapy, and to determine the MTD of combined therapy.
- Conditions
- NPC, HNSCC, Recurrence, Metastasis
- Trial name
- NCT06719479
- Testing
- IAE0972+ Methotrexate, IAE0972+Docetaxel, IAE0972+Gemcitabine
- Volunteers
- 60 people
- Sponsor
- SUNHO（China）BioPharmaceutical CO., Ltd.
Nasopharyngeal Carcinoma by AJCC V8 Stage
Phase II Clinical Study to Compare the Efficacy and Safety of HLX07 + Serplulimab +Chemotherapy Versus Placebo + Serplulimab + Chemotherapy in First-Line Treatment of Patients With Recurrent or Metastatic NPC
A Randomized, Double-Blind, Multi-Center Phase II Clinical Study to Compare the Efficacy and Safety of HLX07 (Recombinant Anti-EGFR Humanized Monoclonal Antibody Injection) + Serplulimab (HLX10, Recombinant Anti-PD-1 Humanized…
- Trial name
- NCT05513573
- Testing
- HLX07, HLX10, chemotherapy
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Shanghai Henlius Biotech
Head and Neck Squamous Cell Carcinoma
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
This study is a phase II clinical study to explore the efficacy and safety of BL-B01D1 + PD-1 monoclonal antibody combination therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma…
- Trial name
- NCT06437522
- Testing
- BL-B01D1, PD-1 monoclonal antibody
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Recurrent Nasopharyngeal Carcinoma, Metastatic Nasopharyngeal Carcinoma
Famitinib in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma (NPC)
RATIONALE: Famitinib is a tyrosin-inhibitor agent targeting at c-Kit, VEGFR2, PDGFR, VEGFR3, Flt1 and Flt3. Phase I study has shown that the drug's toxicity is manageable.
- Trial name
- NCT01392235
- Testing
- Famitinib
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Nasopharyngeal Carcinoma
Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
The purpose of this randomized controlled Phase II study is to assess the efficacy of PDR001 versus investigator's choice of chemotherapy in patients with advanced nasopharyngeal carcinoma (NPC).
- Trial name
- NCT02605967
- Testing
- Spartalizumab, Investigator choice of chemotherapy
- Where
- 18 sites in United States, China and 5 more
- Volunteers
- 122 people
- Sponsor
- Novartis Pharmaceuticals
Nasopharyngeal Neoplasms
Gemcitabine and Oxaliplatin (GEMOX) in First Line Metastatic or Recurrent Nasopharyngeal Carcinoma
Primary objective: To evaluate the response rate of biweekly gemcitabine and oxaliplatin (the GEMOX regimen) in the first line treatment of metastatic or recurrent nasopharyngeal carcinoma.
- Trial name
- NCT00436800
- Testing
- Gemcitabine, Oxaliplatin
- Where
- Hong Kong
- Volunteers
- 41 people
- Sponsor
- Sanofi
Recurrent or Metastatic Nasopharyngeal Cancer, Patients Who Have Experienced Treatment Failure at Least Second-line Chemotherapy
JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal Cancer
This study is a randomized, open-label, multicenter Phase II clinical study, with the objective to assess the efficacy and safety of JMT101 Injection combined with Mitoxantrone Hydrochloride Liposome Injection in patients with…
- Trial name
- NCT06892431
- Testing
- Mitoxantrone Hydrochloride Liposome, JMT101 injection, Capecitabine
- Volunteers
- 150 people
- Sponsor
- Shanghai JMT-Bio Inc.
Nasopharyngeal Carcinoma
A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
This study is a randomized, double-blind, multi-center phase III clinical study to compare the efficacy and safety of penpulimab combined with chemotherapy and placebo combined with chemotherapy in the first-line treatment of…
- Trial name
- NCT04974398
- Testing
- Penpulimab
- Where
- 56 sites in United States, Australia and 3 more
- Volunteers
- 296 people
- Sponsor
- Akeso
Recurrent or Metastatic Nasopharyngeal Carcinoma
A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.
This is a multicenter, open-label, Phase Ib/II study conducted in China to evaluate the safety, efficacy, and pharmacokinetic (PK) characteristics of YL201 combined with Toripalimab (doublet regimen) or YL201 combined with…
- Trial name
- NCT07258979
- Testing
- YL201, Toripalimab, Cisplatin
- Where
- 20 sites in China
- Volunteers
- 202 people
- Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
Head and Neck Cancer
Photodynamic Therapy in Treating Patients With Recurrent, Refractory, or Second Primary Head and Neck Cancer That Cannot Be Treated With Surgery or Radiation Therapy
RATIONALE: Photodynamic therapy uses light and drugs that make cancer cells more sensitive to light to kill tumor cells. This may be an effective palliative treatment for head and neck cancer.
- Trial name
- NCT00003856
- Testing
- temoporfin
- Where
- 7 sites in United States
- Volunteers
- 75 people
- Sponsor
- Quintiles, Inc.
Nasopharyngeal Carcinoma
A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(PANKU-NPC01)
A phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with recurrent or metastatic nasopharyngeal carcinoma who had failed at least two lines of platinum-based…
- Trial name
- NCT06118333
- Testing
- BL-B01D1, capecitabine, gemcitabine
- Where
- China
- Volunteers
- 386 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Nasopharyngeal Carcinoma, Recurrent or Metastatic
KL-A167 Injection in Recurrent or Metastatic Nasopharyngeal Carcinoma
The study is to evaluate the efficacy of KL-A167 injection in subjects with recurrent/metastatic Nasopharyngeal Carcinoma, as measured by Overall Response Rate (ORR) per the Response Evaluation Criteria in Solid Tumors RECIST…
- Trial name
- NCT03848286
- Testing
- KL-A167 Injection
- Where
- China
- Volunteers
- 153 people
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Recurrent or Metastatic Nasopharyngeal Cancer
Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer (NPC)
This study was designed to compare the efficacy and safety of tislelizumab (BGB-A317) combined with gemcitabine plus cisplatin versus placebo combined with gemcitabine plus cisplatin as first-line treatment for recurrent or…
- Trial name
- RATIONALE-309 (NCT03924986)
- Testing
- Tislelizumab, Gemcitabine, Cisplatin
- Where
- 37 sites in China, Taiwan and 1 more
- Volunteers
- 263 people
- Sponsor
- BeiGene
Nasopharyngeal Neoplasms
Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma
The purpose of this study is to evaluate the safety and efficacy of CC-486 in previously treated patients with locally advanced or metastatic nasopharyngeal carcinoma having failed one to two previous regimens, including…
- Trial name
- NCT02269943
- Testing
- CC-486
- Where
- 25 sites in United States, Canada and 7 more
- Volunteers
- 36 people
- Sponsor
- Celgene
Nasopharyngeal Neoplasms
Study of Pembrolizumab (MK-3475) in Platinum Pre-treated Recurrent/Metastatic Nasopharyngeal Cancer (MK-3475-122/KEYNOTE-122)
This is a study of pembrolizumab (MK-3475) versus standard treatment (capecitabine, gemcitabine, or docetaxel) for the treatment of recurrent or metastatic nasopharyngeal cancer (NPC).
- Trial name
- NCT02611960
- Testing
- Pembrolizumab, Capecitabine, Gemcitabine
- Volunteers
- 233 people
- Sponsor
- Merck Sharp & Dohme LLC
Nasopharyngeal Carcinoma (NPC)
A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy
The study is to explore the reasonable dosage and to evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in patients with recurrent/metastatic Nasopharyngeal Carcinoma (NPC) who failed or are intolerant to…
- Trial name
- NCT06839066
- Testing
- HLX43 DOSE 1, HLX43 DOSE 2, HLX43 DOSE 3
- Where
- 15 sites in China
- Volunteers
- 70 people
- Sponsor
- Shanghai Henlius Biotech